Veru (VERU) Q3 2024 earnings summary

Executive summary

• Achieved full enrollment of over 150 patients in the Phase 2b QUALITY clinical trial of enobosarm plus semaglutide for obesity, with topline results expected January 2025.

• Focused on late-stage development of enobosarm in combination with GLP-1 receptor agonists for high-quality weight loss, with ongoing oncology and ARDS programs pending external funding.

• Research and development expenses decreased significantly as the company prioritized enobosarm and paused other programs.

• Cash position improved to $29.2M as of June 30, 2024, up from $9.6M at September 30, 2023, following a $35.2M public stock offering.

• FC2 sales in the global public health sector increased, while U.S. prescription channel sales declined due to lower volume and customer bankruptcy.

Financial highlights

• Q3 FY24 net revenues were $4.0M, up from $3.3M year-over-year; gross profit was $1.3M (34% margin), up from $1.2M (37%).

• Operating expenses dropped to $12.4M from $19.7M, mainly due to reduced R&D and SG&A costs.

• Net loss for Q3 FY24 was $11.0M ($0.07/share), improved from $12.5M ($0.14/share) year-over-year.

• Nine-month net revenues were $10.2M (down from $12.4M), with a net loss of $29.3M, a significant improvement from $85.0M loss in the prior year.

• Gross profit for the nine months was $3.2M (31% margin), down from $6.0M (48% margin) year-over-year.

Outlook and guidance

• Topline Phase 2b QUALITY trial results expected January 2025; extension study results in Q2 2025.

• Plans to engage FDA and potential partners after Phase 2b data readout.

• Advancement of enobosarm for obesity is the primary focus; further development of sabizabulin for ARDS is contingent on external funding.

• Current cash and expected FC2 sales are anticipated to fund operations for the next 12 months.

• The company may seek additional capital through debt, equity, or other financing alternatives as needed.